# A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma

> **NCT03730142** · PHASE1 · COMPLETED · sponsor: **Shanghai Jiatan Pharmatech Co., Ltd** · enrollment: 82 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** WXFL10030390

## Key facts

- **NCT ID:** NCT03730142
- **Lead sponsor:** Shanghai Jiatan Pharmatech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-25
- **Primary completion:** 2020-07-25
- **Final completion:** 2020-07-25
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03730142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03730142, "A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03730142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*